BIC ITALY 8-10 SEPTEMBER 2023
INTERNATIONAL CONFERENCE | WWW.BICCONFERENCE.ORG

10th September - h. 15:30-16:30

CHAIRS:	S. Lacroix (France)	M. Makris (UK)	C. Denis (France)	P. Lenting (France)
	PRINCE OF SALINA - IL GATTOPARDO	DONNA FRANCA FLORIO	KING FREDERICK II "STUPOR MUNDI"	LUIGI PIRANDELLO
15:30	PO 06 - HAEMOPHILIA HEMOPHILIA A MICROENVIRONMENT INDUCES MORPHOLOGICAL AND TRANSCRIPTIONAL CHANGES IN BRAIN MICROVASCULAR ENDOTHELIAL CELLS - S. Assanelli (Italy)	PO 20 - HEMOPHILIA therapy A SIMULATION STUDY TO PROVIDE GUIDANCE FOR INDIVIDUALS TRANSITIONING FROM EMICIZUMAB TO VALOCTOCOGENE ROXAPARVOVEC - S. Pipe (United States)	PO 40 - VON WILLEBRAND DISEASE STRUCTURE-RESOLVED PHENOTYPING OF FIFTEEN VON WILLEBRAND DISEASE TYPE 2M MUTATIONS - A. Tischer (United States)	PO 16 - HEMOPHILIA inhibitor FVIII-SPECIFIC IGA ANTIBODIES AND HISTORY OF HEPATITIS C VIRUS INFECTION: A CROSS-SECTIONAL NATIONWIDE STUDY IN PERSONS WITH HEMOPHILIA A - I. Oomen (The Netherlands)
15:40	PO 05 - HAEMOPHILIA PSYCHOMETRIC VALIDATION OF THE HEMOPHILIA FUNCTIONAL ABILITY SCORING TOOL (HEMO-FAST) - E. Bednar (Sweden)	PO 28 - HEMOPHILIA therapy PSEUDOTUMOR MANAGEMENT DURING EMICIZUMAB PROPHYLAXIS: A TIGHT CORNER - S. Arcudi (Italy)	PO 41 - VON WILLEBRAND DISEASE STRUCTURE-RESOLVED CHARACTERIZATION OF THE VON WILLEBRAND MUTATIONS R1379C/S/L AND A1381T - A. Tischer (United States)	PO 19 - HEMOPHILIA inhibitor THE EFFECT OF DNA METHYLATION ON INHIBITOR DEVELOPMENT IN HEMOPHILIA A PATIENTS TREATED WITH FVIII CONCENTRATES - H. Chand (Italy)
15:50	PO 08 - HAEMOPHILIA MULTISTAKEHOLDER PERSPECTIVES ON PATIENT CENTRICITY: LEVERAGING THE KNOWLEDGE LIVED EXPERIENCE EXPERTS TO ADVANCE THE CURRENT MODEL OF CARE - L. Valentino (United States)	PO 27 - HEMOPHILIA therapy ANNUAL BLEEDING RATES DURING THE FIRST YEAR OF EMICIZUMAB PROPHYLAXIS: PRELIMINARY RESULTS OF THE BRAZILIAN EMICIZUMAB REGISTRY (EMCASE PROJECT) - R.M. Camelo (Brazil)	PO 45 - VON WILLEBRAND DISEASE OPTIMIZING TREATMENT OF PREGNANT WOMEN WITH VON WILLEBRAND DISEASE: A RETROSPECTIVE ANALYSIS OF FACTOR REPLACEMENT THERAPY DURING DELIVERY - W. Al Arashi (The Netherlands)	PO 14 - HEMOPHILIA inhibitor SIALYLATION OF IMMUNODOMINANT PEPTIDES IS AN ATTRACTIVE STRATEGY TO INDUCE TOLERANCE TO FVIII - E. Nardini (The Netherlands)
16:00	PO 12 - HEMOPHILIA inhibitor ICOS DOMAIN IN THIRD-GENERATION FVIII-SPECIFIC CHIMERIC ANTIGEN RECEPTOR HAS A POSITIVE IMPACT ON PHENOTYPE AND ANTIGEN-SPECIFIC RESPONSE OF ENGINEERED REGULATORY T CELLS - S. Scatigna (Germany)	PO 23 - HEMOPHILIA therapy DESMOPRESSIN RESPONSE IN BLEEDING DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS - S. Laan (The Netherlands)	PO 43 - VON WILLEBRAND DISEASE LABORATORY AND CLINICAL PHENOTYPE OF TYPE 2B VON WILLEBRAND DISEASE: 18-YEARS FOLLOW- UP OF 63 PATIENTS- C. Van Kwawegen (The Netherlands)	PO 18 - HEMOPHILIA inhibitor STABILIN-2 ON LIVER SINUSOIDAL ENDOTHELIAL CELLS AS A NOVEL TARGET FOR TOLERANCE INDUCTION TO FVIII - M. Leoni (The Netherlands)
16:10	PO 10 - HAEMOPHILIA PHARMACOKINETICS OF FACTOR IX WITH ONE- STAGE AND CHROMOGENIC ASSAY IN HEMOPHILIA B AND CLINICAL OUTCOME - B. Koc (Turkey)	PO 24 - HEMOPHILIA therapy EFFECTIVENESS AND SAFETY OF DAMOCTOCOG ALFA PEGOL IN PATIENTS WITH HEMOPHILIA A WITH A HISTORY OF FACTOR VIII INHIBITORS: INTERIM ANALYSIS FROM THE REAL-WORLD HEM-POWR STUDY - G. Castaman (Italy)	PO 11 - HAEMOPHILIA THIRD INTERIM ANALYSIS FROM B-MORE: A 24-MONTH PROSPECTIVE, MULTICENTRE, NON INTERVENTIONAL STUDY ON THE REAL-WORD EFFECTIVENESS AND USAGE OF RECOMBINANT FACTOR IX FC (RFIXFC) IN HAEMOPHILIA B - E. Bednar (Sweden)	PO 13 - HEMOPHILIA inhibitor QUANTIFICATION OF FVIII-SPECIFIC CD4+ REGULATORY T CELLS IN HEALTHY DONOR PERIPHERAL BLOOD: A RECENT CLUE IN UNDERSTANDING TOLERANCE TO FVIII - V. Porcheddu (France)
16:20	POSSIBLE REPEAT TIME	POSSIBLE REPEAT TIME	POSSIBLE REPEAT TIME	